Speakers in the Industrial Pre-Event

Miika Leminen is Innovation Director at CGI, where he is responsible for the AI-functionalities in the OMNI360 customer- and patient-information systems. By training he holds both a psychology degree and a Master of Science in Engineering. Earlier in his career, Miika served as the head of the Data Lake and AI Application Services unit at HUS (Helsinki University Hospital) and worked as a brain-research engineer at the University of Helsinki’s Cognitive Brain Research Unit. At CGI, Miika’s mission is to harness the potential of AI technologies into large-scale, practical benefits for social and healthcare professionals.

Chair of the Board and co‑founder at HippocrAItes. A veteran technology and payments leader, Pekka has held senior international roles across EMEA (Europe, the Middle East, and Africa), developing and scaling payment systems for leading institutions including Osuuspankki Group, Visa International, and Ikano Group. He has repeatedly brought new technologies to market and sees in healthcare the same kind of industry inflection he once witnessed in banking.

“Fundamental changes happen in industries when technology, regulation, and standards evolve simultaneously.”

— Pekka Honkanen

Baedr Kayali is an experienced pharmaceutical leader and General Manager of AbbVie Finland. Before that he has held several senior roles at AbbVie in Canada and Europe, Dubai and USA. AbbVie is one of the world’s largest pharmaceutical companies, developing treatments for serious diseases with a focus on immunological and neurological diseases, oncology and hematology, and eye diseases.

Antti has over 20 years of experience of pre-clinical drug development and working with global pharmaceutical and biotech industry.  His primary responsibility is to provide through his team and network pertinent services to the drug development industry where time, money and success are closely tied together. During past 20 years he has witnessed changes in the industry where traditional drug development tools and approaches are being challenged by the use of new advanced methods, NAMs, such as human stems cells, organoids, AI, and chip-based technologies.

Juhana Frösen is a Professor of Neurosurgery at Tampere University. His research has focused on the pathobiology of cerebrovascular diseases causing various forms of brain hemorrhage, with a special emphasis on finding new solutions to predict and prevent brain hemorrhage in different age groups. In addition, as a clinical neurosurgeon, Prof. Frösen treats patients with various kinds of tumors or degenerative conditions affecting the brain and spine, and as such is looking at ways to introduce the predictive and preventine P4 medicine not just to cerebrovascular diseases and the prevention of stroke, but to neurosurgical manifestations of cancer and aging as well.

Sami Lakka is the CEO and Founder of LAKKA Health, company focusing on developing world’s smallest blood pressure monitor Siiring. Sami holds PhD from Tampere University on Measurement and Information Systems, and he has been working solely with medical and wellness devices since 2020. ​​

Joose Kreutzer is the CEO and co-founder of BioGenium Microsystems, a Tampere University spin-off developing engineering systems that keep cells and tissues in physiologically relevant conditions as nature intended. He leads the development of OxyGenie™, a portable mini-incubator that brings precise O₂/CO₂ and temperature control straight to microscopes and analyzers, enabling chronic hypoxia/physoxia, rapid ischemia-like shifts, and defined oxygen gradients within workflows to make your cell culture more in vivo-like. BioGenium’s platforms support applications from cancer-cell hypoxia to engineered heart tissues and Drosophila genetics, integrating organ-on-chip, microfluidics, and sensing to maintain true-to-physiology environments.

Heidi Haikala is an Assistant Professor of Cancer Biology and leads the HaikaLab Immuno-oncology Research Group at the University of Helsinki & Tampere University. Her current research focuses on drug resistance and immune evasion in lung cancer, with a strong emphasis on developing functional, patient-derived models, including ex vivo 3D co-cultures and organ-on-chip platforms. Dr. Haikala is also co-founder and CSO of Solid IO, a spin-off company that develops tumor-on-chip–based diagnostics to guide therapy selection in the clinic.